Corteva Completes Seed Spin-Off as Vylor Starts NYSE Trading; 15 States and Guam Sue Over PFAS Liabilities

One Share Becomes Two, and the Math Only Works If You Squint

On Thursday, investors who owned one share of Corteva woke up owning two things instead: that same Corteva share, now worth a lot less, and a brand-new share in a company called Vylor. Before 9:30 a.m. in New York, Corteva finished handing out all the stock in Vylor, its seed business, to its own shareholders — one Vylor share for every Corteva share they held as of September 24^[1][2]. Vylor then opened for trading on the New York Stock Exchange under the ticker VYLR and immediately took Corteva's old seat in the S&P 500^[3][4].

By the end of the day, Corteva's stock had fallen about 83%^[6]. Read that number on its own and it looks like a disaster. It isn't one. Corteva closed near $12.75 a share, down from $77.65 the day before — but Vylor closed its first day near $68.26^[5][19]. Add the two together and a shareholder who held one Corteva share Wednesday was holding about $81 worth of stock Thursday night. The value didn't vanish. It split.

That same Thursday, a separate and much messier story landed: 15 states and the territory of Guam sued Corteva in an Indiana state court, arguing that the split was designed to put the company's best assets out of reach of people suing over PFAS, the "forever chemicals" tied to DuPont's legacy^[7][8]. Two true things, happening on the same day, pulling in opposite directions — a tidy corporate restructuring on one hand, an accusation of legal evasion on the other.

What "Forever Chemicals" Has to Do With a Seed Company

To understand why a seed spinoff triggered a lawsuit, you need the family tree. Corteva was created in 2019 when DowDuPont broke itself into three companies. One of its ancestors, old DuPont, made PFAS compounds for decades — chemicals used in things like nonstick coatings that don't break down in the environment and have been linked to health problems. That history has left Corteva facing thousands of PFAS lawsuits, even though Corteva itself says it never made or sold the chemicals^[7].

Since 2021, Corteva, DuPont, and a third company called Chemours have shared the cost of PFAS claims under an agreement capping their combined exposure at up to $4 billion^[14]. In 2023, the three paid $1.19 billion to settle claims brought by water utilities^[15]. The costs are real and ongoing. The question the new lawsuit raises is which company's bank account will be the one actually paying them going forward.

That's where "fraudulent transfer" comes in — a legal idea at the center of the states' case. The basic rule is simple: a company can't move its most valuable assets into a new entity while leaving its debts behind in the old one, especially not if the move leaves the original company unable to pay what it owes. The states argue that's exactly what happened here, with Old DuPont's seed "crown jewels" going into Vylor while the PFAS liabilities stayed put^[7][8]. Corteva disputes that characterization and calls the claims "speculative and unproven^[7]."

Two Boards, One Logic: Smaller Can Be Worth More

Corporate spinoffs run on a specific piece of investor logic sometimes called the "conglomerate discount": the idea that a company selling two unrelated things — say, seeds and crop chemicals — often trades for less than the two businesses would be worth split apart. Investors who want seed-business exposure don't want to also buy chemical-business risk, and vice versa, so a combined stock satisfies neither group fully and gets valued at a discount for it.

Corteva's management argues that's exactly what's happened to it. "The seed and crop protection markets have evolved," the company said, pointing to the idea that each business now needs its own strategy and its own investors to reach its full value^[17]. Vylor, led by Corteva's former CEO Chuck Magro, starts out claiming a $19 billion product pipeline and a goal of $11.2 to $11.9 billion in sales by 2029^[7][16]. The remaining Corteva, now a pure crop-chemicals company, was valued at roughly $8.26 billion after its first day of trading^[19].

Not everyone on Wall Street is convinced the split helps. Bank of America analyst Matthew DeYoe said it lacked "clear strategic or financial merit" and warned that splitting the companies could fray the research ties that hold together products like Enlist, a system that pairs crop varieties bred to tolerate certain weedkillers with the weedkillers themselves — a product that only works if seed and chemical research stay connected^[17]. Morningstar, meanwhile, set a $20 fair-value estimate on the post-split Corteva^[18].

A Fight California Already Lost Once

The states' case didn't start on Thursday. Before the split closed, California's attorney general, Rob Bonta, tried to stop it in federal court, arguing the move would leave the leftover Corteva financially unstable and unable to cover future PFAS judgments^[11][12]. A federal appeals court briefly revived his bid to keep fighting, but on remand, the district court denied the request to block the split^[12][13]. By the time Thursday arrived, the deal was already done.

That timing matters more than it might seem. Stopping a corporate transaction before it happens is a different legal fight than unwinding one after it's closed — generally a much harder one, since assets, contracts, and shareholders have already moved on the strength of the deal^[12][13]. So instead of an injunction, the 15 states and Guam filed a new lawsuit, this time aimed at undoing a transaction that already exists rather than preventing one.

A separate, earlier federal filing — made before the split closed, by California and 20 other states — put a number on what they say moved: about $39 billion in assets into Vylor, against a $3.56 billion cash payment left behind for the old company^[9]. Corteva has not conceded that framing, and maintains the PFAS claims driving the lawsuit remain unproven^[7].

Reading the Same Spinoff From Three Different Desks

Coverage of the split broke down less by ideology than by audience. Financial and farm-trade outlets covered it as a routine, even positive, value-unlocking event — emphasizing Vylor's 4.5% first-day stock gain, its S&P 500 debut, and its $19 billion pipeline claim, often without mentioning the lawsuit at all^[4][5][16]. Reuters, by contrast, led with the states' allegation that the spinoff was a bid to "evade" PFAS liabilities — a word choice pulled directly from the plaintiffs, though the story did carry Corteva's denial and noted the coalition of states crossed party lines^[7].

Agri-Pulse, an agriculture trade outlet, split the difference: it reported the states were "citing" PFAS liabilities, a word that frames the connection as the plaintiffs' claim rather than as settled fact^[8]. Overseas, coverage was thinner and almost entirely framed around farm markets rather than the lawsuit. Brazil's Revista Cultivar and Canada's RealAgriculture described the split as a reorganization of who sells seeds versus who sells crop chemicals, with the PFAS fight barely registering^[21][22]. Stocktwits ran a headline describing Corteva's stock hitting a "record low," a framing that reads as a crash to anyone who doesn't already know the lost value reappeared in Vylor shares^[6].

What Happens to a Lawsuit That Arrives After the Money Has Already Moved

For now, two separate public companies exist where one did before: Vylor, holding the seed business and the S&P 500 seat, and a much smaller Corteva, holding crop chemicals^[3][4]. Farmers, who are the actual customers of both businesses, have so far seen no reported changes in price or supply — Vylor has promised a hybrid wheat launch in 2027, but that's a forecast, not something that's happened yet^[17][22].

The real unresolved question sits in the Indiana courtroom, not on the stock ticker. The states need to convince a court to reverse a transaction that's already closed, using the same fraudulent-transfer theory that failed to stop it in advance^[7][12][13]. Corteva will continue to argue the PFAS claims against it remain unproven, and that the cost-sharing deal already in place with DuPont and Chemours is the right mechanism for handling whatever liability does materialize^[7][14]. Whichever company — or companies — eventually end up paying for decades of PFAS contamination is a question the stock market has already priced into two separate tickers. The courts haven't settled it yet.